{
  "slug": "atopic-dermatitis",
  "title": {
    "zh": "異位性皮膚炎：亞洲管線與全球對手",
    "en": "Atopic dermatitis: Asian pipelines and global competitors"
  },
  "answer": {
    "zh": "截至 2026-11-14，異位性皮膚炎的亞洲參與者包括先聲藥業的 rademikibart、中外製藥原研的 nemolizumab，以及中國抗體的 SM17；三者分別涉及 IL-4Rα、IL-31RA 與 IL-25 受體路徑。全球核准對手包括 dupilumab 與 lebrikizumab。協和麒麟已於 2026-03-03 宣布停止 rocatinlimab 的所有進行中試驗，另列歷史退出項目。",
    "en": "As of 2026-11-14, Asian participation in atopic dermatitis includes Simcere’s rademikibart, Chugai-originated nemolizumab and SinoMab’s SM17, targeting IL-4Rα, IL-31RA and the IL-25 receptor pathway, respectively. Approved global comparators include dupilumab and lebrikizumab. Kyowa Kirin announced discontinuation of all ongoing rocatinlimab trials on 2026-03-03; it is listed separately as a discontinued program."
  },
  "scope": {
    "zh": "聚焦具名全身性生物藥；未完整收錄口服 JAK 抑制劑與外用藥。原研與區域開發權分開描述。",
    "en": "Selected systemic biologics; oral JAK inhibitors and topical medicines are not exhaustively covered. Originator and regional rights are distinguished."
  },
  "as_of": "2026-11-14",
  "window_start": "2026-08-17",
  "window_end": "2026-11-14",
  "rows": [
    {
      "id": "ad-simcere",
      "company": {
        "zh": "先聲藥業／Connect",
        "en": "Simcere / Connect"
      },
      "asset": "rademikibart",
      "asia": true,
      "mechanism": {
        "zh": "抗 IL-4Rα 抗體",
        "en": "Anti-IL-4Rα antibody"
      },
      "stage": {
        "zh": "第三期完成；NDA 撤回並擬重送",
        "en": "Phase 3 completed; NDA withdrawn with resubmission planned"
      },
      "indication": {
        "zh": "中重度異位性皮膚炎",
        "en": "Moderate-to-severe atopic dermatitis"
      },
      "route": {
        "zh": "皮下",
        "en": "SC"
      },
      "latest": {
        "zh": "04-22 公告 NDA 已撤回，預計當月重送；本輪查無重送受理的一手確認。",
        "en": "The 04-22 release says the NDA was withdrawn, with resubmission planned that month; primary confirmation of reacceptance was not identified."
      },
      "date": "2026-04-22",
      "sources": [
        {
          "url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0422/2026042202120.pdf",
          "title": "Simcere HKEX regulatory update",
          "date": "2026-04-22",
          "accessed_at": "2026-11-15"
        },
        {
          "url": "https://www.simcere.com/en/news/detail.aspx?mtt=1587",
          "title": "Simcere RADIANT-AD",
          "date": "2026-03-30",
          "accessed_at": "2026-11-15"
        }
      ],
      "trials": "",
      "deal": {
        "zh": "先聲持有中國區域開發、製造與商業化權；本表未核金額",
        "en": "Simcere holds China development, manufacturing and commercialization rights; amounts not verified"
      },
      "history": false,
      "checked_at": "2026-11-14"
    },
    {
      "id": "ad-chugai",
      "company": {
        "zh": "中外製藥；Galderma 等區域夥伴",
        "en": "Chugai; Galderma and regional partners"
      },
      "asset": "nemolizumab / NEMLUVIO",
      "asia": true,
      "mechanism": {
        "zh": "抗 IL-31RA 抗體",
        "en": "Anti-IL-31RA antibody"
      },
      "stage": {
        "zh": "已核准；各地適應症有別",
        "en": "Approved; indications vary by jurisdiction"
      },
      "indication": {
        "zh": "異位性皮膚炎／相關搔癢，依地區標籤",
        "en": "Atopic dermatitis / associated pruritus, per local labels"
      },
      "route": {
        "zh": "皮下",
        "en": "SC"
      },
      "latest": {
        "zh": "中外公告 nemolizumab 研發成果獲獎；這是研究獎項，非新適應症核准。",
        "en": "Chugai announced a drug-discovery award for nemolizumab; this is a research award, not a new indication approval."
      },
      "date": "2026-09-07",
      "sources": [
        {
          "url": "https://www.chugai-pharm.co.jp/english/news/detail/20260907153000_1284.html",
          "title": "Chugai nemolizumab award",
          "date": "2026-09-07",
          "accessed_at": "2026-11-15"
        }
      ],
      "trials": "",
      "deal": {
        "zh": "查無已核實交易條款",
        "en": "No verified deal terms identified"
      },
      "history": false,
      "checked_at": "2026-11-14"
    },
    {
      "id": "ad-sinomab",
      "company": {
        "zh": "中國抗體（香港）",
        "en": "SinoMab (Hong Kong)"
      },
      "asset": "SM17",
      "asia": true,
      "mechanism": {
        "zh": "抗 IL-25 受體（IL17RB）抗體",
        "en": "Anti-IL-25 receptor (IL17RB) antibody"
      },
      "stage": {
        "zh": "第二期；登錄為收案中",
        "en": "Phase 2; recruiting per registry"
      },
      "indication": {
        "zh": "中重度異位性皮膚炎",
        "en": "Moderate-to-severe atopic dermatitis"
      },
      "route": {
        "zh": "皮下",
        "en": "SC"
      },
      "latest": {
        "zh": "公告中國第二期於 03-31 完成首例給藥；預計收案約 210 人，非已完成收案。",
        "en": "Reported first dosing in China Phase 2 on 03-31; approximately 210 participants are planned, not confirmed enrolled."
      },
      "date": "2026-04-01",
      "sources": [
        {
          "url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0401/2026040102996.pdf",
          "title": "SinoMab HKEX first patient dosed",
          "date": "2026-04-01",
          "accessed_at": "2026-11-15"
        },
        {
          "url": "https://clinicaltrials.gov/study/NCT07445919",
          "title": "SM17 Phase 2 registry",
          "date": "2026-04-06",
          "accessed_at": "2026-11-15"
        }
      ],
      "trials": "NCT07445919",
      "deal": {
        "zh": "查無已核實交易條款",
        "en": "No verified deal terms identified"
      },
      "history": false,
      "checked_at": "2026-11-14"
    },
    {
      "id": "ad-sanofi",
      "company": {
        "zh": "賽諾菲／Regeneron",
        "en": "Sanofi / Regeneron"
      },
      "asset": "dupilumab / Dupixent",
      "asia": false,
      "mechanism": {
        "zh": "抗 IL-4Rα 抗體",
        "en": "Anti-IL-4Rα antibody"
      },
      "stage": {
        "zh": "已核准",
        "en": "Approved"
      },
      "indication": {
        "zh": "異位性皮膚炎；年齡依地區",
        "en": "Atopic dermatitis; ages depend on jurisdiction"
      },
      "route": {
        "zh": "皮下",
        "en": "SC"
      },
      "latest": {
        "zh": "加拿大與 pCPA 完成含兒童異位性皮膚炎的意向書談判；意向書不等於各省已給付。",
        "en": "Signed a Canadian pCPA letter of intent including pediatric AD; this does not establish reimbursement in every province."
      },
      "date": "2026-10-15",
      "sources": [
        {
          "url": "https://sanoficanada.mediaroom.com/2026-10-15-Sanofi-and-pCPA-Sign-Letter-of-Intent-for-Dupixent-R-Across-Four-Indications-in-Dermatology-and-Respiratory-Care",
          "title": "Sanofi Canada pCPA LOI",
          "date": "2026-10-15",
          "accessed_at": "2026-11-15"
        }
      ],
      "trials": "",
      "deal": {
        "zh": "查無已核實交易條款",
        "en": "No verified deal terms identified"
      },
      "history": false,
      "checked_at": "2026-11-14"
    },
    {
      "id": "ad-lilly",
      "company": {
        "zh": "禮來",
        "en": "Eli Lilly"
      },
      "asset": "lebrikizumab / EBGLYSS",
      "asia": false,
      "mechanism": {
        "zh": "抗 IL-13 抗體",
        "en": "Anti-IL-13 antibody"
      },
      "stage": {
        "zh": "已核准",
        "en": "Approved"
      },
      "indication": {
        "zh": "中重度異位性皮膚炎",
        "en": "Moderate-to-severe atopic dermatitis"
      },
      "route": {
        "zh": "皮下",
        "en": "SC"
      },
      "latest": {
        "zh": "第三季財報列入手足異位性皮膚炎第三期研究結果；非本頁新增核准宣告。",
        "en": "Q3 results highlighted Phase 3 hand-and-foot AD data; this is not a new approval announcement."
      },
      "date": "2026-10-29",
      "sources": [
        {
          "url": "https://investor.lilly.com/node/55191",
          "title": "Lilly Q3 2026 results",
          "date": "2026-10-29",
          "accessed_at": "2026-11-15"
        }
      ],
      "trials": "",
      "deal": {
        "zh": "查無已核實交易條款",
        "en": "No verified deal terms identified"
      },
      "history": false,
      "checked_at": "2026-11-14"
    },
    {
      "id": "ad-kyowa",
      "company": {
        "zh": "協和麒麟",
        "en": "Kyowa Kirin"
      },
      "asset": "rocatinlimab",
      "asia": true,
      "mechanism": {
        "zh": "抗 OX40 抗體",
        "en": "Anti-OX40 antibody"
      },
      "stage": {
        "zh": "已終止；歷史第三期項目",
        "en": "Discontinued; historical Phase 3 program"
      },
      "indication": {
        "zh": "中重度異位性皮膚炎等",
        "en": "Moderate-to-severe AD and other indications"
      },
      "route": {
        "zh": "皮下",
        "en": "SC"
      },
      "latest": {
        "zh": "因新出現安全性疑慮，宣布停止所有進行中試驗。",
        "en": "Announced discontinuation of all ongoing trials following emerging safety concerns."
      },
      "date": "2026-03-03",
      "sources": [
        {
          "url": "https://www.kyowakirin.com/media_center/news_releases/2026/e20260303_01.html",
          "title": "Kyowa Kirin discontinuation",
          "date": "2026-03-03",
          "accessed_at": "2026-11-15"
        }
      ],
      "trials": "",
      "deal": {
        "zh": "查無已核實交易條款",
        "en": "No verified deal terms identified"
      },
      "history": true,
      "checked_at": "2026-11-14"
    }
  ]
}
